



## Late-breaking Abstract Submission Deadline: June 26, 2025, 11:59 p.m., ET

### Preparation Instructions and Online Submission

Please read the following guidelines and rules thoroughly before preparing your abstract. Abstracts not adhering to these rules will not be reviewed. Below are the steps you will find when you enter the abstract submission system.

#### Online Abstract Submission Information and Steps

Submission Deadline.....	p. 2
Technical Support.....	p. 2
Important Guidelines.....	p. 2
Step 1: General Information.....	p. 3
Step 2: Keywords.....	p. 7
Step 3: Scientific Information.....	p. 7
Step 4: Authors.....	p. 8
Step 5: Sponsor.....	p. 9
Step 6: Schedule Conflicts.....	p. 10
Step 7: Additional Information.....	p. 10
Step 8: Author Disclosures.....	p. 11
Step 9: Confirmation.....	p. 11

#### Additional Abstract and Program Information

Review Process.....	p. 11
Program Assignment Notification.....	p. 12
Withdrawal.....	p. 12
Copyright.....	p. 12
Disclaimer.....	p. 12
Embargo.....	p. 12

## Submission Deadline

The ASBMR welcomes your scientific abstract submission to the ASBMR 2025 Annual Meeting. **Abstracts must be submitted by Thursday, June 26, 2025, at 11:59 pm, ET.** It is your responsibility to ensure that the abstract is entered online by the deadline. All abstracts must be submitted using the ASBMR Abstract Center and may be accessed via the ASBMR website at <https://meeting.asbmr.org/>.

## Technical Support

Technical Assistance is available **Monday - Friday, 9:00 a.m. - 5:00 p.m. ET** by calling +1 (202) 367-1161 or emailing [abstracts@asbmr.org](mailto:abstracts@asbmr.org). Should you need assistance after hours or over the weekend, please email to the address above and ASBMR staff will respond on the next business day.

## Important Guidelines

- **New for 2025! Early Career level abstracts do not require a sponsor. However, Mid-Career and Senior Career level abstracts must be sponsored by a current ASBMR member. Contact ASBMR offices at [abstracts@asbmr.org](mailto:abstracts@asbmr.org) if you are uncertain about your sponsor's membership status.**
- No two abstracts and/or presentations that share one or more authors may overlap significantly in content.
- Please use the "Schedule Conflicts" section to indicate any schedule conflicts of which you are aware that would preclude your presenting your abstract on a certain day(s) or at a specific time of the meeting (September 5-8, 2025). Please be aware that the ASBMR will **NOT** make any changes once the abstracts have been assigned to the program.
- If a manuscript associated with an abstract has appeared in print or online on or before **Thursday, June 26, 2025**, the abstract is **not** eligible for oral presentation at the ASBMR 2025 Annual Meeting and should be submitted for **Poster Presentation Only**.
- ASBMR understands that limited data may be available at the time of the submission deadline. Initiated trial abstracts will be accepted and considered for oral or poster presentation at the Annual Meeting. The abstract submission should detail the trial design and rationale, inclusion criteria, primary clinical endpoints, and any available preliminary data. Lead investigators are encouraged to submit if additional data is anticipated to be available for presentation by the first day of the ASBMR Annual Meeting
- Authors of an abstract describing a study funded by an organization with a proprietary or financial interest must identify the organization and affirm that they had full access to all the data in the study under the "Additional Information" section. By so doing, they accept complete responsibility for the integrity of the data and the accuracy of the data analysis.
- After submitting your abstract, please read your text online to ensure accuracy. **No corrections will be accepted after the abstract submission deadline of Thursday, June 26, 2025, 11:59 pm, ET.**

## STEP 1: GENERAL INFORMATION

### Abstract Title

1. Make the title brief, clearly indicating the nature of the investigation.
2. Do **NOT** use all capitalized or all lowercase letters. (Correct Example: This Is the Title of the Abstract)
3. Do **NOT** use ending punctuation in your title.
4. Do **NOT** enter your entire abstract in the title entry area.

5. If you need to use a symbol within the title, click on the “insert custom character” icon within the title toolbar.

## **Abstract Review Categories**

Select the abstract category that best suits your abstract. Please note that the categories are divided into either Basic OR Clinical OR Translational Categories. Please take care to select the appropriate review category for your abstract.

### Basic Categories

- Adult Metabolic Bone Disorders, (e.g., Paget, CKD, Diabetes and Secondary Causes)
- Bone Cell Biology, (e.g., Stem/Progenitor Cells, Osteoclasts, Osteoblasts and Osteocytes)
- Bone Marrow Microenvironment and Cancer and Metastasis
- Hormone, Energy Metabolism and Crosstalk with Other Tissues
- Lifestyle including Physical Activity, Vitamin D, Microbiota, Nutrition and Nutritional Supplements
- Mechanobiology, Biomechanics and Bone Quality
- Musculoskeletal Aging, Inflammation and Senescence
- Musculoskeletal Development
- Omics Approaches for Musculoskeletal Biology, Diseases and Treatments
- Osteoarthritis and Other Joint Disorders and Bone/Joint Health Services Research
- Osteoporosis – Assessment
- Osteoporosis - Treatment
- Pediatric Bone Disorders, Bone Acquisition and Bone Health in Special Populations
- Rare Bone Diseases
- Sarcopenia, Muscle and Falls
- Tissue Engineering, Regeneration and Fracture Healing

### Translational Categories

- Adult Metabolic Bone Disorders, (e.g., Paget, CKD, Diabetes and Secondary Causes)
- Bone Cell Biology, (e.g., Stem/Progenitor Cells, Osteoclasts, Osteoblasts and Osteocytes)
- Bone Marrow Microenvironment and Cancer and Metastasis
- Hormone, Energy Metabolism and Crosstalk with Other Tissues
- Lifestyle including Physical Activity, Vitamin D, Microbiota, Nutrition and Nutritional Supplements
- Mechanobiology, Biomechanics and Bone Quality
- Musculoskeletal Aging, Inflammation and Senescence
- Musculoskeletal Development
- Omics Approaches for Musculoskeletal Biology, Diseases and Treatments
- Osteoarthritis and Other Joint Disorders and Bone/Joint Health Services Research
- Osteoporosis – Assessment
- Osteoporosis - Treatment
- Pediatric Bone Disorders, Bone Acquisition and Bone Health in Special Populations
- Rare Bone Diseases
- Sarcopenia, Muscle and Falls
- Tissue Engineering, Regeneration and Fracture Healing

### Clinical Categories

- Adult Metabolic Bone Disorders (e.g., Paget, CKD, Diabetes and Secondary Causes)
- Bone Cell Biology, (e.g., Stem/Progenitor Cells, Osteoclasts, Osteoblasts and Osteocytes)
- Bone Marrow Microenvironment and Cancer and Metastasis
- Clinical Cases
- Hormone, Energy Metabolism and Crosstalk with Other Tissues
- Lifestyle including Physical Activity, Vitamin D, Microbiota, Nutrition and Nutritional Supplements
- Mechanobiology, Biomechanics and Bone Quality
- Musculoskeletal Aging, Inflammation and Senescence
- Musculoskeletal Development
- Omics Approaches for Musculoskeletal Biology, Diseases and Treatments
- Osteoarthritis and Other Joint Disorders and Bone/Joint Health Services Research
- Osteoporosis – Assessment
- Osteoporosis - Epidemiology
- Osteoporosis - Treatment

- Pediatric Bone Disorders, Bone Acquisition and Bone Health in Special Populations
- Rare Bone Diseases
- Sarcopenia, Muscle and Falls
- Tissue Engineering, Regeneration and Fracture Healing

## **ASBMR Annual Meeting Travel Grants**

### **ASBMR Young Investigator Annual Meeting Travel Grant**

The Young Investigator Travel Grant is awarded to the top Young Investigators who are selected to present an oral or plenary poster presentation at the ASBMR Annual Meeting. ASBMR Young Investigator Travel Grants will provide \$500 for North American-based applicants and \$750 for all other applicants. Eligible applicants must:

- Be an ASBMR member paid through the end of 2025
- Be the first and presenting author of the abstract
- Be a student/trainee or within five (5) years of completion of a Ph.D., M.D., residency training or equivalent.\*
- Have not received any other ASBMR-funded travel or young investigator support for the 2025 Annual Meeting.

\*The 5 years of eligibility are defined to extend from the end of the calendar year of the date of graduation or, if applicable, of completion of residency training or clinical subspecialty fellowship training, to the submission deadline date. Clinical subspecialty fellowship training is considered to end no later than the point at which the individual becomes board eligible. To petition for an extension of eligibility, please contact the ASBMR prior to the abstract submission deadline.

### **ASBMR Family Care Travel Grant**

The Family Care Travel Grant provides financial support to offset the cost of childcare, eldercare, or other family care, enabling meeting attendees with dependents more financial freedom to attend the ASBMR Annual Meeting. The Family Care Travel Grant provides \$400 to each recipient. Eligible applicants must:

- Be the first and presenting author of a submitted abstract to the ASBMR Annual Meeting
- Be an ASBMR member paid through the end of 2025
- Have at least one (1) dependent

Recipients receiving any other ASBMR-funded travel or young investigator travel support for the Annual Meeting are also eligible to receive a Family Care Travel Grant, assuming they meet the program's eligibility criteria.

The grant is intended to offset any of the following expenses so that the recipient may attend the annual meeting:

- Dependent care expenses (incurred at home or in the annual meeting city)
- Expenses incurred in bringing a caregiver and/or dependent(s) to the annual meeting city
- Travel of a relative or caregiver to the recipient's home to care for a dependent(s)
- Travel of the recipient's dependent(s) to the location of a relative or caregiver

Only one (1) Family Care Grant per family is permitted.

## **Copyright Transfer Agreement**

In consideration of the actions of the American Society for Bone and Mineral Research ("ASBMR") in reviewing and editing this abstract, we do hereby irrevocably assign and transfer all right, title and interest in and to the copyright in the abstract, in its current form or in any form subsequently revised for publication in any language and in all media now known or hereafter developed, including, without limitation, print, microform, and electronic media, any and all renewals and extensions of such copyright that may be secured under the laws now or hereafter pertaining thereto in the United States and any and all causes of action heretofore accrued for infringement of said copyright, to the ASBMR and its successors and assigns. The ASBMR grants each of the authors the following royalty-free rights, subject only to acknowledgement of the ASBMR's copyright:

- Reproduce and distribute to a colleague a copy of the published abstract, in whole or in part, for the colleague's personal or professional use.
- Reuse any of the figures, tables and the abstract in a book or book chapter edited or written by any of the authors.
- Reuse figures, tables and the abstract in a journal article written by any of the authors.

- Reproduce and distribute the abstract for student use in courses taught by any of the authors at academic/research institutions.
- Reproduce and distribute the abstract in whole or part for presentation by any of the authors at scientific or professional conferences.

Authors do not need to contact the ASBMR for permission to re-use their own materials as specified above.

Authors do not need to contact the ASBMR for permission to re-use their own materials as specified above. A JBMR® Supplement serves as a compiled version of the Abstracts. Select abstracts may also be reproduced in the ASBMR's open access journal *JBMR® Plus*. Any reproduction of the abstract in whole, or in part, must be accompanied by an acknowledgement of the ASBMR's copyright in the following form: Reproduced from J Bone Miner Res Year; Volume: Page Numbers with permission of the American Society for Bone and Mineral Research. © American Society for Bone and Mineral Research, year.

Please indicate your agreement to the above policy by checking the appropriate box.

## STEP 2: KEYWORDS

Select 3 Keywords from the below list and/or add original keywords related to your abstract submission.

Adult	Muscle
Anti-resorptives	Musculoskeletal development
Blood cells	Musculoskeletal regeneration
Bone - bone marrow	Musculoskeletal stem/progenitor cells
Bone - ligament	Neuroendocrine regulation
Bone - periosteum	Osteoblasts
Bone anabolics	Osteoclasts
Bone biomarkers	Osteocytes
Bone marrow niche	Osteopetrosis
Cancer and metastasis	Osteoporosis
Cartilage - articular	Pediatric Bone Disease
Cartilage - growth plate	Phosphate and mineral metabolism
Chondrocytes	Physical activity
Circadian rhythm	Preclinical model, computational
Craniofacial and dental	Preclinical model, large animals
Depression	Preclinical model, mouse, gain-of-function
Diabetes and obesity	Preclinical model, mouse, loss-of-function
Diet	Preclinical model, organ culture and other in vitro models
Diet manipulations	Preclinical model, rodent, others
Disorders of Calcium and Phosphate	Preclinical model, zebrafish
Energy and glucose metabolism	Rare Bone Diseases
Fracture healing	Sarcoma
Genomics	Sarcopenia
Glucose metabolism	Senescence
GWAS	Sympathetic nervous system
Hormonal regulators	Techniques, histology
Immune cells	Techniques, histomorphometry
Inflammation	Techniques, immunolabelling
Joints	Techniques, radiograph
Kidney disease	Therapeutics
Metabolomics	Tissue engineering
Mineral metabolism	Transcriptomics

## STEP 3: SCIENTIFIC INFORMATION

### Abstract Body

1. If you are submitting more than one abstract, the abstracts may NOT overlap significantly in content.

2. Your abstract may have up to 2500 characters (including spaces). This does not include the title, authors or attachments.
3. Do NOT include your title, author information and affiliation(s), sponsor or category within your abstract text. Enter ONLY your abstract text.
4. Do NOT mention support of work by a research grant within the body of the abstract.
5. Do NOT include identifiable information within the abstract body, such as references to previous work or citations, to prevent bias during the review process.
6. Do NOT underline, bold or use capitals for emphasis in the abstract text.
7. Single space all text. Do NOT place blank lines between paragraphs.
8. Do NOT place hard returns at the end of each line; use hard returns only to start a new paragraph.
9. Organize the content of the abstract by first stating the purpose, describing the methods used, summarizing the results presented in sufficient detail to support the conclusions and state the conclusions reached. (It is not satisfactory to state, "The results will be discussed" or "Other data will be presented" for initiated trials see the "important guidelines" section.
10. To enter abstract text, you can begin typing or pasting your text from Microsoft Word or another application. Please review the document to ensure that the style and format is correct. **No corrections will be accepted after the abstract submission deadline of Thursday, June 26 2025, 11:59 pm, ET.**

**Standard abbreviations are required and are available for reference in the following citations:**

1. Instructions to Authors, J.Biol.Chem. 252:10, 1977.
2. StyleBook: Manual of Style, American Medical Association, 9<sup>th</sup> Edition, Baltimore, 1998.

Acceptable abbreviations may be used without definition. Some standard abbreviations may be unfamiliar to large numbers of readers; at the author's discretion, these may also be defined. Abbreviations not listed in the references cited above must be defined by placing them in parentheses after the full word the first time they appear. **Excessive use of other than standard abbreviations may jeopardize evaluation of the abstract for scientific merit.** Use numerals to indicate numerals except when they begin sentences. Nonproprietary (generic) names not capitalized are required the first time a drug is mentioned. Proprietary names are always capitalized, e.g., acetazolamide (Diamox).

## Graphics and Tables

1. You may upload one image as an attachment to your abstract submission. Attachments are accepted in .jpg, .gif or .png formats.
2. Please remove extraneous white space surrounding the graphic by cropping it prior to submitting your abstract.
3. The recommended graphic size to optimize resolution is 3.5 inches wide by 3 inches tall and an absolute minimum of 600 DPI. **Remember:** When the abstract is reduced to fit in a column in the *Abstracts* book, the image must be legible. If you are not sure whether your image is the appropriate size, please contact [abstracts@asbmr.org](mailto:abstracts@asbmr.org) for assistance.
4. Images will be placed at the end of the abstract. **Please be sure to label your image as you would want it to appear in the Abstracts book.**

## STEP 4: AUTHORS

1. You must identify at least one author as the presenter for your abstract and one author as the Principal Investigator. To begin, click the "Add Author" link. Enter information for each author in all open fields. **PLEASE NOTE: The order of authors can be changed by clicking the Move button and dragging and dropping the name into your preferred sequence.**

2. **Presenting Authors must be fluent in English and able to answer questions.** If none of the authors are fluent in English, you must check the “Poster Only” option within the “Additional Information” section of the abstract submission system.
3. The presenting author will be the main contact for this abstract. Please be sure that all contact information is up to date. If the Presenting/Contact Author’s address or other contact information changes between abstract submission and the time of the meeting, it is that author’s responsibility to update the contact information within the online submission program.
4. It is expected that the individual identified as the Presenting Author at the time of submission will present the abstract at the meeting. Presenting Author changes can be made only due to special circumstances or unavoidable schedule conflicts that arise after the submission deadline that will preclude the participation of the individual initially identified for this role.

## Disputes

ASBMR will not adjudicate a dispute between abstract presenters.

## Expectations of Authors and Presenters

Through ASBMR meetings, the Society promotes excellence in the bone, mineral and musculoskeletal field. To that end, ASBMR expects that all authors and presenters affiliated with the ASBMR 2025 Annual Meeting will provide informative and fully accurate content that reflects the highest level of scientific rigor and integrity.

**The ASBMR depends upon the honesty of the authors and presenters and relies on their assertions that they have had sufficient full access to the data and are convinced of its reliability.**

Attendees to the ASBMR 2025 Annual Meeting include basic scientists and clinicians from over 65 countries. To improve comprehension of your research by a diverse audience, we ask that the language you use in your presentation be clear and concise. Please attempt to avoid jargon and unnecessarily complicated language. Clearly define all terms, experimental techniques, abbreviations and acronyms that are not typically known outside your area of expertise. Where appropriate, please provide control reference ranges and baselines. Consider the use of a statement of relevance such as ‘These clinical findings are consistent/inconsistent with current thinking on the mechanisms of action...’ or ‘These basic findings could suggest a possible therapeutic target...’

Further, the ASBMR expects that:

- All authors and presenters (invited and abstracts-based oral and poster presenters) will disclose any conflicts of interest, real or perceived.
- Authors of an abstract describing a study funded by an organization with a proprietary or financial interest must affirm that they had full access to all the data in the study. By so doing, they accept complete responsibility for the integrity of the data and the accuracy of the data analysis.
- The content of abstracts, presentations, slides and reference materials must remain the ultimate responsibility of the author(s) or faculty.
- The planning, content and execution of abstracts, speaker presentations, slides, abstracts and reference materials should be free from corporate influence, bias, or control.
- All authors and presenters (invited and abstracts-based oral and poster presenters) should give a balanced view of therapeutic options by providing several treatment options, whenever possible, and by always citing the best available evidence.

In addition, ASBMR meeting evaluations will seek feedback regarding commercial bias.

## STEP 5: SPONSOR

**New for 2025! Early Career level abstract submissions DO NOT require a sponsor. However, Mid-Career and Senior Career level abstracts must be sponsored by a current member of the ASBMR.** A member may sponsor only ONE abstract; however, you may co-author any number of abstracts. Current members in the following categories may sponsor their own abstracts: In-Training, APDEM, Full, and Discounted.

**Please Note:** Mid-Career and Senior Career level abstracts without sponsorship from a current member will not be



reviewed. If you would like to become an ASBMR member and sponsor your own abstract, please visit our website at [www.asbmr.org](http://www.asbmr.org) and click on “Join ASBMR.” Contact ASBMR offices at [abstracts@asbmr.org](mailto:abstracts@asbmr.org) if you have any membership questions.

## STEP 6: SCHEDULE CONFLICTS

Please use the “Schedule Conflicts” section to indicate any schedule conflicts of which you are already aware that would preclude your presenting your abstract on a certain day(s) or at a specific time of the meeting (September 5-8, 2025). Leave this section blank if you have no schedule conflicts. Please be aware that the ASBMR will **NOT** make any scheduling changes once the abstracts have been assigned to the program.

## STEP 7: ADDITIONAL INFORMATION

### Prior Publication and Presentation Policy

Abstracts submitted to the ASBMR 2025 Annual Meeting represent recent advances bone, mineral and musculoskeletal, and those abstracts highlighted at the oral program present the most cutting-edge research in the bone, mineral and musculoskeletal field. Authors should carefully review our prior publication policy, below, to determine if their abstracts are eligible for consideration for the oral program or for poster presentation only.

At the time of abstract submission, the manuscript should not have been previously published **verbatim** as a scientific article or meeting abstract. Note that interim research products, including manuscripts deposited to a preprint server, **are** eligible for abstract submission.

If a manuscript associated with an abstract has or will appear in print or online on or before **Thursday, June 26, 2025** (excluding a preprint server), the abstract is **not** eligible for oral presentation at the ASBMR 2025 Annual Meeting and should be submitted for **Poster Presentation Only**. It is the submitting author’s responsibility to select “Poster Only” from the drop-down menu in the Additional Information section.

### Prior Presentation

Wide dissemination of previously presented abstracts **excludes** oral presentation at the ASBMR 2025 Annual Meeting. The following guidelines apply to previously presented abstracts:

1. Abstracts presented orally or as a poster at a prior ASBMR Annual Meeting may not be submitted for either poster or oral presentation.
2. Abstracts that have received *wide exposure* may not be submitted for an oral presentation at the ASBMR 2025 Annual Meeting and should be marked “Poster Only” under the Preferences section on the Submission Site.

Examples of *wide exposure* include presentation (poster or oral) at major U.S. and other national and international meetings.

Examples of meetings at which abstracts have been presented that would **not** exclude oral presentation at the ASBMR 2025 Annual Meeting include focused workshops and symposia such as: Gordon Conferences, Advances in Mineral Metabolism, ASBMR Topical Meeting and Keystone Symposia.

If you have previously presented the material in your abstract at another meeting and are not sure about its eligibility for oral presentation at the ASBMR 2025 Annual Meeting, please mark “Poster Only” or contact ASBMR ([abstracts@asbmr.org](mailto:abstracts@asbmr.org)) for advice before submitting the abstract.

### Funding Information

Authors of an abstract describing a study funded by an organization with a proprietary or financial interest must identify the organization and affirm that they had full access to all the data in the study. By doing so, they accept complete responsibility for the integrity of the data and the accuracy of the data analysis.

### IRB Disclosure

It is the author’s responsibility to ensure that all clinical investigations detailed in abstracts are conducted in accordance with the Declaration of Helsinki. Authors must also document that these studies have been approved by the appropriate



institutional human research committee. Identifying information for study participants should not be published within written descriptions, photographs or pedigrees or test results. *If such information is included as essential scientific information, the authors must submit written consent of patient or guardian to publish such information in the proceedings of this meeting.*

## Animal Care and Use Disclosure

It is the author's responsibility to assure that all experimental procedures are in compliance with the guiding principles in the "Guide for the Care and Use of Laboratory Animals" available online at: [http://www.nap.edu/catalog.php?record\\_id=5140](http://www.nap.edu/catalog.php?record_id=5140)

Authors must document that their studies were approved by the appropriate institutional animal care and oversight committee and have available documentation that these studies were approved.

## Photography by the Media and/or Medical Journalists

While general attendees are not allowed to take photos during scientific sessions, the ASBMR does allow media and medical journalists to take photos of select presentations to assist in their coverage of the research being presented at the ASBMR Annual Meeting. By indicating your approval during the abstract submission process, this saves you time and interruption prior to your presentation at the Annual Meeting with the media approaching you for signed approval.

**NOTE:** The media are not allowed to directly reproduce/report data or use photos of presentation slides. The photography will only be used for the purpose of reporting on your presentation and will provide your research and your additional exposure in the field.

## Generative Artificial Intelligence (Gen AI)

The ASBMR will allow the use of Generative Artificial Intelligence (Gen AI) tools, including large-scale language modeling (LLM) tools, with proper documentation (name, vendor, version, date used, how it was used) in abstracts that are submitted for consideration in the ASBMR 2025 Annual Meeting scientific program. Abstract authors are responsible for the accuracy and integrity of the content produced and generated by Gen AI, along with acquiring the appropriate rights and permissions. Gen AI (including LLM) tools do not meet author or co-author requirements and therefore cannot be listed as authors or co-authors in the abstract submission.

# STEP 8: AUTHOR DISCLOSURES

## Disclosure/Conflict of Interest

The ASBMR is committed to ensuring the balance, independence, objectivity and scientific rigor of all its individually sponsored or industry-supported educational activities. Accordingly, the ASBMR adheres to the requirement set by ACCME that audiences at jointly-sponsored educational programs be informed of a presenter's (speaker, faculty, author, or planner) academic and professional affiliations, and the disclosure of the existence of any significant financial interest or other relationship a presenter or their spouse has with any proprietary entity over the past 12 months producing, marketing, re-selling or distributing health care goods or services, consumed by or used on patients, with the exemption of non-profit or government organizations and non-health care related companies. When an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose, is discussed during the presentation, it is required that presenters disclose that the product is not labeled for the use under discussion or that the product is still investigational. This policy allows the listener/attendee to be fully knowledgeable in evaluating the information being presented. The On-Site Program book will note those speakers who have disclosed affiliations, including the nature of the affiliation and the associated commercial entity.

Disclosure should include any affiliation that may bias one's presentation or which, if known, could give the perception of bias. This includes the relevant financial affiliations of a spouse or partner. If an affiliation exists that could represent or be perceived to represent a conflict of interest, this must be reported in the abstract submission program by listing the name of the commercial entity and selecting the potential conflict(s) by clicking in the box next to the affiliation type. Disclosures will be printed in the program materials. These situations may include, but are not limited to:

1. Grant/Research Support
2. Consultant
3. Speakers' Bureau
4. Major Stock Shareholder
5. Other Financial or Material Support

## STEP 9: SUBMITTAL AND PAYMENT

Please use this page to review your submission. **NO CHANGES OR CORRECTIONS WILL BE ACCEPTED AFTER THE SUBMISSION DEADLINE, Thursday, June 26, 2025, at 11:59 pm, ET.**

The submitter is responsible for ensuring that all information is entered correctly. Corrections may be made to the abstract using the online submission program until the submission deadline.

### Abstract Submission Fees

The abstract submission fee is \$175 USD. Payment must accompany each abstract submission. VISA, MASTERCARD, and AMERICAN EXPRESS are accepted for payment of abstract submission fees. The abstract submission fee is non-refundable. Please take care to provide complete and accurate information. If you need to pay using a different mechanism, please contact the ASBMR Business Office at [abstracts@asbmr.org](mailto:abstracts@asbmr.org) or +1 (202) 367-1161.

### Abstract Receipt Confirmation

The final step in the online submission process generates a confirmation receipt of the submission. Please print this page for your records. An email record of the transaction will be sent to you. You can review the confirmation page at any time by viewing the Submittal and Payment section of your abstract.

## ADDITIONAL ABSTRACT AND PROGRAM INFORMATION

### Review Process

The ASBMR is sensitive to issues of commercial confidentiality and relevant aspects of the U.S. Securities and Exchange Commission (SEC) regulations. Therefore, all ASBMR reviewers are required to adhere to the SEC regulations and treat all information as confidential. ASBMR abstract reviewers are instructed that they may be viewed as an “insider” by the SEC due to their knowledge of information included in abstracts, particularly clinical trial abstracts. All ASBMR abstract reviewers are required to adhere to confidentiality agreements prior to receiving abstracts.

In addition to protecting the confidentiality of any material received, reviewers must record their conflict(s), if any, and abstain from scoring the abstract(s) if any conflict of interest arises.

Abstracts will be peer-reviewed, according to category. All abstracts are entered into the ASBMR Abstracts Database. The information from each abstract is captured within different fields in the Database. To ensure absolute impartiality in the reviewing process, a “blinded” copy of each abstract will be generated for the review process. “Blinded” copies will not include author or institutional field information, but rather the title and body of your abstract only. The abstract reviewers will score abstracts based on the merit of the submission only.

### Program Assignment Notification

**By the mid-July 2025**, you will receive an e-mail notifying you of your program assignment. It is the responsibility of the presenting author/submitter to notify the other authors of the abstract. **Please note: Program Assignment Letters are e-mailed to the presenting author and the email address used during the submission. Please ensure the presenting author will have access to the email address used in the submission when notifications are sent by ASBMR staff.**

### Withdrawal

All requests to withdraw an abstract must be received in writing at the ASBMR Business Office. **Abstracts may not be withdrawn after July 23, 2025**, unless an acceptable explanation is received. An acceptable reason for withdrawal is the inability to reproduce data in the abstract. The abstract submission fee is non-refundable.

### Copyright

Abstracts submitted to the ASBMR 2025 Annual Meeting are copyrighted by the American Society for Bone and Mineral Research and published in the *Journal of Bone and Mineral Research (JBMR®)*. Reproduction, distribution or transmission of the abstracts, in whole or in part, by any means, is prohibited without the express written permission of the American Society for Bone and Mineral Research. Please see list of retained author rights in the Copyright Transfer Agreement section above.

## Disclaimer

All authored abstracts, findings, conclusions, recommendations or oral presentations are those of the author(s) and/or speaker(s) and do not reflect the views of the American Society for Bone and Mineral Research or imply any endorsement. No responsibility is assumed, and responsibility is hereby disclaimed, by the American Society for Bone and Mineral Research for any injury and/or damage to persons or property as a matter of products' liability, negligence or otherwise, or from any use or operation of methods, products, instructions or ideas presented in the abstracts or at the ASBMR 2025 Annual Meeting. Independent verification of diagnosis and drug dosages should be made. Discussions, views and recommendations regarding medical procedures, choice of drugs and drug dosages are the responsibility of the authors and presenters.

## Embargo

The ASBMR is sensitive to issues of commercial confidentiality and relevant aspects of the U.S. Securities and Exchange (SEC) regulations. Therefore, the ASBMR reminds all readers that everyone must adhere to the SEC regulations and treat all scientific information as confidential until the embargo has been lifted. The embargo lifts at the start time of the session in which the presentation is being made. Any reader of, or listener to, ASBMR 2025 Annual Meeting content may be viewed as an "insider" by the SEC due to knowledge of information included in abstracts, particularly clinical trial abstracts. SEC regulations may call for criminal penalties for using such information.

**Abstracts submitted to the ASBMR 2025 Annual Meeting are embargoed – that is, unavailable for public release in written, oral or electronic communications – until the start time of the actual presentation at the ASBMR Annual Meeting.** Public release includes presentation of data by the presenting author, colleagues, or others (1) in writing, on the internet or in other electronic formats, (2) orally in interviews or at other sessions/meetings that are not part of this official ASBMR program and/or take place before the embargo is lifted, (3) at the ASBMR 2025 Annual Meeting before the embargo is lifted and (4) in traditional text publications (e.g., journals, newspapers, newsletters) that will be published before the embargo is lifted. In addition, ASBMR reminds presenters and attendees that other organizations and entities' embargoes should be honored. Any issues that arise in relation to this policy should be promptly reported to the ASBMR Executive Director in writing. This is a longstanding ASBMR policy that will be enforced.